AI 보조前列腺암 진단에 대한 배치 안전 사례.
PMID: 40345136 ·
Y, a, n, , J, i, a, ;, , C, l, a, r, e, , V, e, r, r, i, l, l, ;, , K, i, e, r, o, n, , W, h, i, t, e, ;, , M, o, n, i, c, a, , D, o, l, t, o, n, ;, , M, a, r, g, a, r, e, t, , H, o, r, t, o, n, ;, , M, u, f, a, d, d, a, l, , J, a, f, f, e, r, j, i, ;, , I, b, r, a, h, i, m, , H, a, b, l, i
광고
초록
Deep learning (DL) has the potential to deliver significant clinical benefits. In recent years, an increasing number of DL-based systems have been approved by the relevant regulators, e.g. FDA. Although obtaining regulatory approvals is a prerequisite to deploy such systems for real world use, it may not be sufficient. Regulatory approvals give confidence in the development process for such systems, but new hazardous events can arise depending on how the systems have been deployed in the intende
광고
공식 출처
PubMed에서 보기 →데이터는 PubMed / NCBI에서 제공됩니다. 전문과 최신 정보는 반드시 공식 기록을 확인하세요.